Avisi Technologies

Avisi Technologies company information, Employees & Contact Information

Avisi is developing a portfolio of ophthalmic treatments based on a novel metamaterial technology. Its flagship product, VisiPlate, is a nanotechnology-enabled implant to treat glaucoma. Glaucoma is the leading cause of irreversible blindness in the world and currently has no cure. To date, Avisi has been supported by venture investors as well as grants and awards from: the National Science Foundation, the University of Pennsylvania, Wharton, The School of Engineering and Applied Science, Penn Law's Entrepreneurship Legal Clinic, the Singh Center for Nanotechnology, and VentureWell. Avisi has been recognized as the winner of the Ophthalmology Technology Summit People’s Choice Award, the Winner of the Glaucoma Research Foundation H. Dunbar Hoskins International Innovations Award, a finalist of the 2022 FIERCE Life Sciences Innovation Awards, one of ten most promising Philadelphia tech companies of the decade in Technical.ly’s RealLIST Startups 2020, a Watchlist venture in Wharton Magazine, and a finalist at the 2019 SXSW Innovation Awards for Health, Med, and Biotech. Avisi is a proud member/alum of Johnson & Johnson JLABS incubator, UCSF Rosenman Innovators, OC OCTANE LaunchPad, and MedTech Innovator Accelerator. Website: www.avisitech.com Twitter: @avisi_tech

Company Details

Employees
20
Founded
-
Address
1733 Woodside Rd, Redwood City,ca 94061,united States
Email
in****@****ech.com
Industry
Medical Equipment Manufacturing
NAICS
Medical Equipment and Supplies Manufacturing
Surgical and Medical Instrument Manufacturing
Surgical Appliance and Supplies Manufacturing
Dental Equipment and Supplies Manufacturing
Ophthalmic Goods Manufacturing
Dental Laboratories
HQ
Redwood City, CA
Looking for a particular Avisi Technologies employee's phone or email?

Avisi Technologies Questions

News

Avisi Technologies Receives FDA Approval to Study Novel Approach to Glaucoma Treatment - Morningstar

Avisi Technologies Receives FDA Approval to Study Novel Approach to Glaucoma Treatment Morningstar

Avisi Technologies Presents Positive Six-Month Clinical Data for VisiPlate® Aqueous Shunt at the American Glaucoma Society - PR Newswire

Avisi Technologies Presents Positive Six-Month Clinical Data for VisiPlate® Aqueous Shunt at the American Glaucoma Society PR Newswire

Top Avisi Technologies Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant